A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer

Cancer, 06/05/2012

The results suggest that a weekly dose of single–agent trastuzumab emtansine (T–DM1) 2.4mg/kg has antitumor activity and is well tolerated in patients with HER2–positive metastatic breast cancer.

Print Article Summary Cat 2 CME Report